Last week I was at home and got a call from a physician who I used to see patients for. He was in his late 50s and the ever-increasing workload in his practice had put a damper on his physical activity; therefore, he had gained some weight. This, of course, …

I have had several patients who did well at first with their GLP-1 agonists. Patient 1: Man, 46 years of age, used liraglutide 3mg daily for obesity. Patients 2 & 3: 2 women in their 60s were using liraglutide for type 2 diabetes & weight.

Drs. Sood and Messer talk with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the positives of their practice model and their difference from other physicians.

In this week's Homerun Slides, the summary of the role of plasma protein (S1P) in glycocalyx protection.

Any discussion of lipid and lipoprotein metabolism in diabetes mellitus, especially type 2 diabetes mellitus (T2DM), must consider the role of insulin resistance (IR). IR plays a central role in the abnormal lipid and lipoprotein metabolism of T2DM [1] as evidenced by the characteristic set of lipid and lipoprotein abnormalities accompanying IR, even in the absence of frank hyperglycemia or abnormal glucose tolerance. Individuals with IR have low plasma levels of HDL-C and elevations in plasma triglyceride (TG) levels compared with levels seen in individuals who have normal insulin sensitivity. There is also an increase in the proportion of low-density lipoprotein (LDL) particles that are small, dense, and cholesterol ester-poor. I